3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
3
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Breast Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Soft Tissue Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Pharyngeal Neoplasms
1
Patients With Advanced or Metastatic Solid Tumors
1
PRETEXT I Hepatoblastoma
1
Neurofibromatosis 2
1
Neoplasms, Mesothelial
1
Mouth Neoplasms
1
Melanoma
1
Lymphangioleiomyomatosis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Glioma
1
Glioblastoma
1
Erdheim-Chester Disease
1
Endometrial Adenocarcinoma
1
Endocrine Gland Neoplasms
1
Colonic Neoplasms
1
Castleman Disease
1
Interventions
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Cisplatin
4
trastuzumab deruxtecan
3
Platinum
3
Docetaxel
3
Carboplatin
3
Biopsy
3
pembrolizumab
2
entrectinib
2
darolutamide
2
Trastuzumab
2
Radiotherapy, Intensity-Modulated
2
Leuprolide
2
Goserelin
2
Ado-Trastuzumab Emtansine
2
1,2-diaminocyclohexaneplatinum II citrate
2
zanidatamab
1
trastuzumab biosimilar HLX02
1
sacituzumab govitecan
1
pyrotinib
1
pertuzumab
1
luprolide acetate gel depot
1
larotrectinib
1
enfortumab vedotin
1
dehydroftorafur
1
ceralasertib
1
camrelizumab
1
bicalutamide
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
temsirolimus
×
90 days
×
Clear all
No trials found.